Literature DB >> 35689933

Population-Based Prevalence of Infarctions on 3D Fluid-Attenuated Inversion Recovery (FLAIR) Imaging.

Petrice M Cogswell1, Jeremiah A Aakre2, Anna M Castillo2, David S Knopman3, Kejal Kantarci4, Alejandro A Rabinstein3, Ronald C Petersen3, Clifford R Jack4, Michelle M Mielke2, Prashanthi Vemuri3, Jonathan Graff-Radford3.   

Abstract

OBJECTIVES: To report population-based, age-specific prevalence of infarctions as identified via 3D fluid-attenuated inversion recovery (FLAIR) imaging.
MATERIALS AND METHODS: Participants without dementia in the Mayo Clinic Study of Aging (MCSA), a population-based study in Olmsted County, MN, age 50-89 who underwent 3D FLAIR imaging between 2017 and 2020 were included. Infarctions per participant were determined via visual interpretation. Inter- and intra-reader reliability were calculated. Infarction prevalence on 3D FLAIR was derived by standardization to the Olmsted County population and was compared to that previously reported on 2D FLAIR imaging.
RESULTS: Among 580 participants (mean age 71 years, 46% female) the prevalence (95% confidence interval) of any infarction was 5.0% (0.0%-9.9%) at age 50-59 years and 38.8% (28.6%-49.0%) at 80-89 years. In addition to increasing with age, the prevalence varied by sex and type of infarction. Prevalence estimates of cortical infarcts were 0.9% (0.0%-2.7%) at age 50-59 years and 20.2% (10.7%-29.7%) at 80-89 years and lacunar infarcts 4.1% (0.0%-8.8%) at age 50-59 years and 31.2% (21.5%-41.0%) at 80-89 years. Prevalence estimates of any infarction by sex were: men, 8.7% (0.0%-18.7%) at 50-59 years and 54.9% (41.0%-68.8%) at 80-89 years and women, 2.4% (0.0%-7.3%) at age 50-59 years and 27.3% (12.9%-41.7%) at 80-89 years. Intra- and inter- reader reliability were very good (kappa = 0.85 and 0.82, respectively). After adjusting for age, sex and education, individuals imaged with 3D FLAIR were 1.5 times (95% CI 1.2-1.8, p<0.001) more likely to be identified as positive for infarction compared to those imaged with 2D FLAIR.
CONCLUSIONS: Infarction prevalence increases with age and is greater in men than women. Infarction prevalence on 3D FLAIR imaging, which has become more widely implemented as an alternative to 2D FLAIR over the past several years, will be a useful reference in future work.
Copyright © 2022 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cerebrovascular disease; Infarction prevalence; Magnetic resonance imaging (MRI); Population studies

Mesh:

Year:  2022        PMID: 35689933      PMCID: PMC9329259          DOI: 10.1016/j.jstrokecerebrovasdis.2022.106583

Source DB:  PubMed          Journal:  J Stroke Cerebrovasc Dis        ISSN: 1052-3057            Impact factor:   2.677


  23 in total

Review 1.  Advances in strategies for minimizing and adjusting for survey nonresponse.

Authors:  R C Kessler; R J Little; R M Groves
Journal:  Epidemiol Rev       Date:  1995       Impact factor: 6.222

2.  Differing risk factor profiles of ischemic stroke subtypes: evidence for a distinct lacunar arteriopathy?

Authors:  Caroline A Jackson; Aidan Hutchison; Martin S Dennis; Joanna M Wardlaw; Arne Lindgren; Bo Norrving; Craig S Anderson; Graeme J Hankey; Konrad Jamrozik; Peter Appelros; Cathie L M Sudlow
Journal:  Stroke       Date:  2010-02-11       Impact factor: 7.914

Review 3.  Mild cognitive impairment as a diagnostic entity.

Authors:  R C Petersen
Journal:  J Intern Med       Date:  2004-09       Impact factor: 8.989

4.  Prevalence and correlates of silent cerebral infarcts in the Framingham offspring study.

Authors:  Rohit R Das; Sudha Seshadri; Alexa S Beiser; Margaret Kelly-Hayes; Rhoda Au; Jayandra J Himali; Carlos S Kase; Emelia J Benjamin; Joseph F Polak; Christopher J O'Donnell; Mitsuhiro Yoshita; Ralph B D'Agostino; Charles DeCarli; Philip A Wolf
Journal:  Stroke       Date:  2008-06-26       Impact factor: 7.914

5.  Prevalence, incidence, and risk factors of lacunar infarcts in a community sample.

Authors:  Xiaohua Chen; Wei Wen; Kaarin J Anstey; Perminder S Sachdev
Journal:  Neurology       Date:  2009-07-28       Impact factor: 9.910

6.  Reliability and validity of NINCDS-ADRDA criteria for Alzheimer's disease. The National Institute of Mental Health Genetics Initiative.

Authors:  D Blacker; M S Albert; S S Bassett; R C Go; L E Harrell; M F Folstein
Journal:  Arch Neurol       Date:  1994-12

7.  Three-dimensional fluid attenuated inversion recovery imaging with isotropic resolution and nonselective adiabatic inversion provides improved three-dimensional visualization and cerebrospinal fluid suppression compared to two-dimensional flair at 3 tesla.

Authors:  Gulzar Hameed Chagla; Reed F Busse; Ryan Sydnor; Howard A Rowley; Patrick A Turski
Journal:  Invest Radiol       Date:  2008-08       Impact factor: 6.016

8.  Stroke subtype, vascular risk factors, and total MRI brain small-vessel disease burden.

Authors:  Julie Staals; Stephen D J Makin; Fergus N Doubal; Martin S Dennis; Joanna M Wardlaw
Journal:  Neurology       Date:  2014-08-27       Impact factor: 9.910

9.  Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration.

Authors:  Joanna M Wardlaw; Eric E Smith; Geert J Biessels; Charlotte Cordonnier; Franz Fazekas; Richard Frayne; Richard I Lindley; John T O'Brien; Frederik Barkhof; Oscar R Benavente; Sandra E Black; Carol Brayne; Monique Breteler; Hugues Chabriat; Charles Decarli; Frank-Erik de Leeuw; Fergus Doubal; Marco Duering; Nick C Fox; Steven Greenberg; Vladimir Hachinski; Ingo Kilimann; Vincent Mok; Robert van Oostenbrugge; Leonardo Pantoni; Oliver Speck; Blossom C M Stephan; Stefan Teipel; Anand Viswanathan; David Werring; Christopher Chen; Colin Smith; Mark van Buchem; Bo Norrving; Philip B Gorelick; Martin Dichgans
Journal:  Lancet Neurol       Date:  2013-08       Impact factor: 44.182

10.  Relation of cerebral vessel disease to Alzheimer's disease dementia and cognitive function in elderly people: a cross-sectional study.

Authors:  Zoe Arvanitakis; Ana W Capuano; Sue E Leurgans; David A Bennett; Julie A Schneider
Journal:  Lancet Neurol       Date:  2016-06-14       Impact factor: 44.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.